EDIT - candlestick chart analysis of Editas Medicine Inc.

Popular stocks today

AAPL AMZN BB BHP CLF CWEB DVN HAL MMC MSFT MSTR NVDA PLTR PYPL QQQ SCHB SPY TD TSLA VOO

Membership
- Log In
- Log Out
- Sign Up
- About HotCandlestick
- Benefits
- Help
Candlestick Charts
Chart Education
Trading Tools
Opportunities
External Links

Official PayPal Seal

As Seen In...

The Complete Guide to Using Candlestick Charting: How to Earn High Rates of Return safely

EDIT Earnings: *Wed 4-JUN-2025

End of day quotes updated Fri Mar 14 15:47 CST
🏠

⎙

🔍

◄ Daily Pattern ► ◄ Weekly Pattern ► ◄ Monthly Pattern ► ◄ Quarterly Pattern ►
Bullish Doji Star Bullish Stick Sandwich Bearish Three Outside Down none
03-Feb-2025 02-Aug-2024 31-Oct-2023 unknown
-131.8 strength 83.1 strength -201.9 strength

EDIT	SPY
6.6 -15.1 -24.0 15.0 15.0	2.1 -2.3 -5.3 -4.0 -4.0
% Price Gain WTD Performance (%) MTD Performance (%) QTD Performance (%) YTD Performance (%)
SPY tracks S&P 500 index.

EDIT News
13-Mar-2025 5:56 AM CST - Yahoo Finance Here's Why Editas Medicine (NASDAQ:EDIT) Must Use Its Cash Wisely So should Editas Medicine (NASDAQ:EDIT) shareholders be worried about its cash burn? For the purposes of this article, cash burn is the annual rate at which an unprofitable compan
5-Mar-2025 3:19 PM CST - Yahoo Finance Editas: Q4 Earnings Snapshot Editas Medicine Inc. EDIT) on Wednesday reported a loss of $45.4 million in its fourth quarter.
5-Mar-2025 3:04 PM CST - Yahoo Finance Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates On track to declare two in vivo editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025Company to present further in vivo HSC preclinical data and further in vivo preclinical data in one liver indication by year-endOn track to establish one additional target cell type/tissue by year-endStrong cash position with operational runway into the second quarter of 2027 CAMBRIDGE,
24-Feb-2025 8:23 AM CST - Business Insider Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March Additionally, Editas Medicine management will participate in the following upcoming investor conferences in March: To access the live webcasts of Editas Medicine's presentations, please visit the "Investors" section of the Company's website at An archived replay will be available for approximately 30 days following each event.
27-Jan-2025 12:10 PM CST - Investing Editas Medicine Inc (EDIT) Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Editas Medicine (NASDAQ:EDIT) Inc on Thursday, setting a price target of $55, which is approximately 72.52%... Chardan Capital ...
16-Jan-2025 5:17 AM CST - Business Insider Bank of America Securities Sticks to Their Sell Rating for Editas Medicine (EDIT) Bank of America Securities analyst Alec Stranahan maintained a Sell rating on Editas Medicine (EDIT - Research Report) yesterday and set a
15-Jan-2025 3:36 AM CST - Business Insider Editas Medicine: Strategic Ambitions and Cautious Optimism in Gene-Editing Advancements Editas Medicine (EDIT - Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu
14-Jan-2025 8:29 AM CST - Yahoo Finance Editas Medicine Outlines 2025 Strategic Priorities and Milestones Editas Medicine ( (EDIT) ) has provided an announcement. Editas Medicine announced new in vivo preclinical proof of concept data and outlined its strategic priorities and key milestones for 2025, aiming to advance its gene editing technologies targeting hematopoietic stem cells and liver cells.
13-Jan-2025 8:27 AM CST - Business Insider Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel

Disclaimer Privacy Contact

Copyright © 2001-2025, All rights reserved.
HotCandlestick.com, LLC

EDIT News
13-Mar-2025 5:56 AM CST - Yahoo Finance Here's Why Editas Medicine (NASDAQ:EDIT) Must Use Its Cash Wisely So should Editas Medicine (NASDAQ:EDIT) shareholders be worried about its cash burn? For the purposes of this article, cash burn is the annual rate at which an unprofitable compan
5-Mar-2025 3:19 PM CST - Yahoo Finance Editas: Q4 Earnings Snapshot Editas Medicine Inc. EDIT) on Wednesday reported a loss of $45.4 million in its fourth quarter.
5-Mar-2025 3:04 PM CST - Yahoo Finance Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates On track to declare two in vivo editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025Company to present further in vivo HSC preclinical data and further in vivo preclinical data in one liver indication by year-endOn track to establish one additional target cell type/tissue by year-endStrong cash position with operational runway into the second quarter of 2027 CAMBRIDGE,
24-Feb-2025 8:23 AM CST - Business Insider Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March Additionally, Editas Medicine management will participate in the following upcoming investor conferences in March: To access the live webcasts of Editas Medicine's presentations, please visit the "Investors" section of the Company's website at An archived replay will be available for approximately 30 days following each event.
27-Jan-2025 12:10 PM CST - Investing Editas Medicine Inc (EDIT) Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Editas Medicine (NASDAQ:EDIT) Inc on Thursday, setting a price target of $55, which is approximately 72.52%... Chardan Capital ...
16-Jan-2025 5:17 AM CST - Business Insider Bank of America Securities Sticks to Their Sell Rating for Editas Medicine (EDIT) Bank of America Securities analyst Alec Stranahan maintained a Sell rating on Editas Medicine (EDIT - Research Report) yesterday and set a
15-Jan-2025 3:36 AM CST - Business Insider Editas Medicine: Strategic Ambitions and Cautious Optimism in Gene-Editing Advancements Editas Medicine (EDIT - Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu
14-Jan-2025 8:29 AM CST - Yahoo Finance Editas Medicine Outlines 2025 Strategic Priorities and Milestones Editas Medicine ( (EDIT) ) has provided an announcement. Editas Medicine announced new in vivo preclinical proof of concept data and outlined its strategic priorities and key milestones for 2025, aiming to advance its gene editing technologies targeting hematopoietic stem cells and liver cells.
13-Jan-2025 8:27 AM CST - Business Insider Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel